Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Change for Ncardia
August 2019
SHARING OPTIONS:

GOSSELIES, Belgium—Ncardia recently announced that in the wake of retracting the Cor.4U product line from the market and insolvency of its former legal entity in Germany (operating under the name Ncardia AG, formerly Axiogenesis), it has increased investment in its Belgian manufacturing site, as well as its R&D and drug discovery center in the Netherlands and commercial operations in the United States. All of the company’s active investors took part in a capital increase. After restructuring, all manufacturing services have been centered at Ncardia’s contract and product manufacturing facility in Gosselies, while drug discovery and safety services will continue at the Leiden, Netherlands headquarters.
 
“We continue our dedication to the advancement of iPSC technologies in the drug discovery space and are excited that with the support of our investors, we can continue providing quality iPSC-derived products and accelerate our capabilities in contract cell manufacturing and drug discovery assay development,” remarked Ncardia CEO Stefan Braam.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.